0001144204-13-001332.txt : 20130108 0001144204-13-001332.hdr.sgml : 20130108 20130108170811 ACCESSION NUMBER: 0001144204-13-001332 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130102 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20130108 DATE AS OF CHANGE: 20130108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vystar Corp CENTRAL INDEX KEY: 0001308027 STANDARD INDUSTRIAL CLASSIFICATION: FABRICATED RUBBER PRODUCTS, NEC [3060] IRS NUMBER: 202027731 STATE OF INCORPORATION: GA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53754 FILM NUMBER: 13518848 BUSINESS ADDRESS: STREET 1: 3235 SATELLITE BOULEVARD STREET 2: BUILDING 400, SUITE 290 CITY: DULUTH STATE: GA ZIP: 30096 BUSINESS PHONE: 770-965-0383 MAIL ADDRESS: STREET 1: 3235 SATELLITE BOULEVARD STREET 2: BUILDING 400, SUITE 290 CITY: DULUTH STATE: GA ZIP: 30096 8-K 1 v331645_8k.htm FORM 8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported) January 2, 2013

 

 

VYSTAR CORPORATION
(Exact name of registrant as specified in its charter)

 

Georgia 000-53754 20-2027731
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

 

3235 Satellite Blvd., Building 400, Suite 290, Duluth GA 30096
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code (770) 965-0383

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a- 12 under the Exchange Act (17 CFR 240.14a- 12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 2, 2013, Paul A. Yeoham, age 48, was appointed to the Baord of Directors of the Company. Mr. Yeoham is a founding partner of Progress Equity Partners, Ltd., a private equity investment firm that acquires majority control of well-managed, entrepreneurial, service-based businesses, and brings with him more than twenty years of financial and investment management experience to the board. Prior to forming Progress Equity, he was a senior partner at Transition Capital Partners, Ltd., a similar private equity firm. Mr. Yeoham joined Transition Capital Partners in 1993 as an associate, while the firm operated as Best Associates, and became a partner in 1996 when the firm changed its name to Best, Patterson, Crothers and Yeoham, Ltd. Mr. Yeoham received a Bachelor's Degree in Business Administration and Finance from the University of Texas at Arlington and a Master's Degree in Business from Southern Methodist University.

 

In addition to the Company, Mr. Yeoham currently serves on the boards of Terracare Associates and Oncology Molecular Imaging, LLC. He has previously served in a similar capacity for the boards of Texas Home Health Holdings, Inc., Tributary Systems, Inc., Digney York Associates, LLC, Network for Medical Communication and Research, LLC (NMCR), Conisus, LLC (Envision Communications) and more recently Westcon, Inc.

 

Mr. Yeoham was granted 400,000 options to purchase Company stock at $.35 per share. Such options vest 20,000 per fiscal quarter of service by Mr. Yeoham to the Company’s Board of Directors beginning March 31, 2013, and continuing for each fiscal quarter thereafter so long as Mr. Yeoham continues to be a member of the Board of Directors on the last day of each such fiscal quarter.

 

Item 9.01.   Financial Statements and Exhibits.

 

   (d) Exhibits

 

Exhibit 99.1 Press Release, dated January 9, 2013

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VYSTAR CORPORATION
January 8, 2013    
     
  By: /s/ William R. Doyle                  
    William R. Doyle
    Chairman, CEO and President
     
     

 

 

 

EX-99.1 2 v331645_ex99-1.htm EXHIBIT 99.1

 

Vystar® Corporation Appoints Founding Partner of ProgressEquity, Paul Yeoham, to Its Board of Directors

 

Brings Valuable M&A Expertise to the Board

 

ATLANTA, January 9, 2013 – Vystar® Corporation (OTCBB: VYST) (“Vystar” or the “Company”), owner of SleepHealth™, a unique provider of sleep health services to physicians in the southeastern U.S., and exclusive creator of Vytex® Natural Rubber Latex (NRL), a multi-patented, all-natural raw material that contains significantly reduced levels of non-rubber particles and proteins found in natural rubber latex, announced today that Paul Yeoham has joined its board of directors effective January 2, 2013, bringing the total number of Vystar board members to seven.

Mr. Yeoham is a founding partner of Progress Equity Partners, Ltd., a private equity investment firm that acquires majority control of well-managed, entrepreneurial, service-based businesses, and brings with him more than twenty years of financial and investment management experience to the board. Prior to forming Progress Equity, he was a senior partner at Transition Capital Partners, Ltd., a similar private equity firm. Mr. Yeoham joined Transition Capital Partners in 1993 as an associate, while the firm operated as Best Associates, and became a partner in 1996 when the firm changed its name to Best, Patterson, Crothers and Yeoham, Ltd. Mr. Yeoham received a Bachelor's Degree in Business Administration and Finance from the University of Texas at Arlington and a Master's Degree in Business from Southern Methodist University.

 

William Doyle, President and CEO of Vystar Corporation, commented, “Paul’s appointment to our Board of Directors comes at a pivotal point in our growth story. With the acquisition of SleepHealth, the recent formation of two important durable medical equipment (DME) partnerships and continued focus on the vertical integration of Vystar businesses, his financial, M&A and operational experience will be pivotal to successfully executing our expansion strategy and evaluating any and all growth opportunities in the year ahead.”


Paul Yeoham stated, “I’m pleased to join Vystar’s board of directors. The Company’s new SleepHealth division and growing DME partners, in addition to its core premium Vytex NRL product, have laid a solid foundation for its next stage of growth which we anticipate will be marked by increased revenue and profitability. I look forward to becoming an integral aspect of their team and to providing the necessary guidance and assistance to help them reach their business objectives.”

In addition to Vystar Corporation, Mr. Yeoham currently serves on the boards of Terracare Associates and Oncology Molecular Imaging, LLC. He has previously served in a similar capacity for the boards of Texas Home Health Holdings, Inc., Tributary Systems, Inc., Digney York Associates, LLC, Network for Medical Communication and Research, LLC (NMCR), Conisus, LLC (Envision Communications) and more recently Westcon, Inc.

 

Other members of Vystar’s Board of Directors include Tom Marsh, President of Centrotrade Minerals and Metals, Inc. (dba: Centrotrade Rubber USA), the technical advisory U.S. based subsidiary of Centrotrade, a leading global distributor of rubber, latex and chemicals; J. Douglas Craft, Founder and Chief Executive Officer of Atlanta-based Medicraft Inc., one of the largest independent distributors for Medtronic since 1984. Over the past ten years, Doug has been actively engaged in expanding the base of businesses to include Intraoperative Neuro-Monitoring, Orthopedics, Biologics, Interventional Pain therapies and Government contracting; JC Allegra, MD, is the Co-Founder of NMCR, an educational organization dedicated to assisting cancer physicians in their utilization of new cancer therapies. Dr Allegra is also the Founder of Lincoln Lee Investments, a family office which supervises the investments of the Allegra Family. Dr Allegra is a NIH/NCI trained medical oncologist who established the new Cancer Medicine Division at the University of Louisville in 1980 and served the University from 1982-1989 as Professor and Chairmen of its Department of Medicine; Mitsy Mangum, Vice President of Investments at Mid-South Capital Inc., helped spearhead the SleepHealth acquisition and has over 25 years of institutional and retail investment experience. She also serves as VP of finance for the Charleston School of Business Club in Atlanta, Georgia; Dean Waters, a seventeen year financial services veteran, is the Founder and Managing Director of FiveFold Capital, an investment banking firm focused on early stage companies and is a former senior executive of Commerce Street Capital, Global Capital Finance, GMAC Commercial Finance, and Bank of America; and William Doyle, President and CEO of Vystar Corporation.

 

 
 

 

About Vystar Corporation

Based in Duluth, GA, Vystar® Corporation (OTC Bulletin Board: VYST) is owner of SleepHealth, a unique provider of sleep health services and durable medical equipment (DME) to patients of physician clients in the southeastern U.S., and the exclusive creator of Vytex Natural Rubber Latex (Vytex NRL), a multi-patented, all-natural, raw material that contains significantly reduced levels of the proteins found in natural rubber latex and can be used in over 40,000 products. Vytex NRL is a 100% renewable resource, environmentally safe, "green" and fully biodegradable. Vystar is working with manufacturers across a broad range of consumer and medical products to bring Vytex NRL to market in adhesives, balloons, surgical and exam gloves, other medical devices and natural rubber latex foam mattresses and pillows. For more information, visit www.vytex.com and www.sleephealthier.com

 

Forward-looking Statements: Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of VYST officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future VYST actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and VYST has no specific intention to update these statements.

 

Investor Contact:

Howard Gostfrand, President

American Capital Ventures

305-918-7000

info@amcapventures.com

 

 

Vystar Corporation

Joanne Kearney, Vice President of Marketing

770-965-0383 x 21